ProQR Therapeutics (PRQR) Non-Current Debt (2016 - 2023)

ProQR Therapeutics (PRQR) has reported Non-Current Debt for 8 consecutive years, with $4.9 million the latest figure, recorded in Q4 2023.

• Quarterly Non-Current Debt changed 0.49% year-over-year to $4.9 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4.9 million (changed 0.49% YoY) and the FY2023 annual result came in at $4.9 million, changed 0.49% from the prior year.
• Non-Current Debt advanced to $4.9 million in Q4 2023 per PRQR's latest filing, from $3.3 million in the prior quarter.
• Over the last five years, Non-Current Debt for PRQR reached as high as $44.7 million in Q4 2021 and fell as low as $3.3 million in Q3 2023.
• A 5-year average of $16.3 million and a median of $13.2 million in 2019 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2021 — Non-Current Debt jumped 246.44% — and 2023, when it slumped 90.54%.
• Year by year, Non-Current Debt stood at $14.5 million in 2019, then advanced by 27.38% to $18.4 million in 2020, then surged by 142.87% to $44.7 million in 2021, then plunged by 89.14% to $4.9 million in 2022, then grew by 0.49% to $4.9 million in 2023.
• According to Business Quant data, Non-Current Debt over the past three periods registered $4.9 million, $3.3 million, and $4.1 million for Q4 2023, Q3 2023, and Q2 2023 respectively.